Alex Adjei, MD, PhD

Prior to taking this position, he was Professor of Oncology, Professor of Pharmacology and Director of Early Cancer Therapeutics at Mayo Clinic in Rochester, Minnesota. 

He was co-chair of the National Cancer Institute's Thoracic Malignancies Steering Committee until 2021, recently served as a member of the National Institute of Health's Blue Ribbon Panel evaluating quality of grant reviews by Oncology Study Sections and also as a member of the National Academy of Science, Engineering and Medicine's Committee on Diagnosis and Treatment of Adult Cancers. He is currently a member of the National Cancer Institute's Board of Scientific Counselors .

He is editor-in-chief of the Journal of Thoracic Oncology, and the JTO Clinical and Research Reports, and has authored over 300 peer-reviewed publications and edited two books. His academic expertise and research is in regulatory science, drug development, early phase trials, pharmacogenetics, novel therapies for lung cancer and academic publishing.

See publications for this provider. (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists collaborate with industry to advance medical breakthroughs. These partnerships help commercialize discoveries for public benefit while maintaining scientific integrity. To ensure transparency and minimize potential bias, Cleveland Clinic reviews these relationships and publicly discloses when physicians/scientists receive significant compensation for consulting, serve in fiduciary roles, receive royalties, or hold equity interests related to their work. We manage potential conflicts through approval processes, annual reporting, and targeted management plans.

As of 2026-02-15, Dr. Adjei has reported no financial relationship with industry that is applicable to this listing.

In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.